https://triveni.bio/news/ 2026-10-13T10:49:31+00:00 https://triveni.bio/triveni-bio-appoints-bhaskar-srivastava-m-d-ph-d-as-chief-medical-officer-announces-key-program-updates/ 2025-09-01T23:27:16+00:00 https://triveni.bio/triveni-bio-doses-first-healthy-volunteers-in-clinical-trial-for-triv-509-coinciding-with-preclinical-data-presentations-further-validating-novel-kallikrein-5-7-biology-in-atopic-dermatitis/ 2025-09-02T14:12:35+00:00 https://triveni.bio/triveni-bio-welcomes-jeff-albers-and-allison-luo-to-its-board-of-directors/ 2025-09-03T16:49:21+00:00 https://triveni.bio/triveni-bio-launches-with-92-million-series-a-financing-to-advance-genetics-informed-precision-medicines-for-the-treatment-of-immunological-and-inflammatory-ii-disorders/ 2025-09-03T16:51:04+00:00 https://triveni.bio/medcity-news-biotech-startup-triveni-unveils-92m-to-address-barrier-to-treating-inflammation/ 2025-09-08T18:24:07+00:00 https://triveni.bio/biopharma-dive-triveni-emerges-from-biotech-merger-with-92m-for-immune-disease-drugs/ 2025-09-08T18:24:38+00:00 https://triveni.bio/stifel-2024-virtual-immunology-and-inflammation-summit/ 2025-09-08T18:25:24+00:00 https://triveni.bio/triveni-bio-raises-115-million-series-b-financing-to-expand-pipeline-of-therapeutics-addressing-immunological-and-inflammatory-ii-disorders/ 2025-09-08T18:25:49+00:00 https://triveni.bio/biopharmadive-news-with-115m-more-triveni-accelerates-immune-drug-work/ 2025-09-08T18:19:52+00:00 https://triveni.bio/fiercebiotech-news-triveni-ropes-in-115m-series-b-less-than-a-year-after-92m-fundraise/ 2025-09-08T18:23:14+00:00 https://triveni.bio/fierce-biotech-names-triveni-bio-a-fierce-15-biotech-company-of-2025/ 2025-09-22T22:09:23+00:00 https://triveni.bio/triveni-doses-first-subject-in-global-phase-2-proof-of-concept-study-of-triv-509-in-atopic-dermatitis-presents-translational-data-at-2025-eadv-congress-demonstrating-novel-biology-in-patient-samples/ 2025-09-23T11:00:20+00:00 https://triveni.bio/triveni-bio-doses-first-healthy-volunteers-with-next-generation-bispecific-antibody-triv-573-targeting-kallikreins-5-7-and-interleukin-13-in-phase-1-clinical-trial/ 2026-05-18T13:08:00+00:00 https://triveni.bio/triveni-bio-raises-65-million-series-c-financing-to-expand-scope-of-first-in-class-bispecific-triv-573-clinical-studies-and-drive-next-stage-company-growth/ 2026-06-17T11:03:21+00:00 https://triveni.bio/triveni-bio-doses-first-patient-in-global-phase-2-proof-of-concept-study-of-triv-573-in-atopic-dermatitis-and-provides-ii-pipeline-update/ 2026-10-13T11:00:00+00:00